에 대한 최신 뉴스 Nukkleus (NASDAQ:NUKK) 주식

Nukkleus

Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).

Nukkleus, Micron, Teva Pharmaceutical, Quantum Computing, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Movers

NUKK

누클레우스(NASDAQ:NUKK)의 주가가 금요일 약 44% 급등했다. 이는 회사가 나스닥 상장 요건을 재확인했다고 발표한 후 계속된 모멘텀으로 보인다.

금요일 누클레우스 주식이 약 44% 상승 마감, 무슨 일이?

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Markets

Trading Ideas

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

OFIX

TMCI

TXNM

VIAV

WILC

버서스 시스템즈(NASDAQ:VS)의 주가는 회사가 국제적인 입지를 성장시키기 위한 전략의 일환으로 회사가 브라질 시장으로의 확장을 발표한 후 급등했다. 버서스 시스템즈의 주가가 금요일 프리마켓 거래에서 71.2% 상승하여 $3.39에 거래되었다.

버서스 시스템즈 주식이 약 71% 상승한 이유: 프리마켓에서 움직이는 20개의 주식

Ticker,Board,With,Stock,Market,Prices,,Percentage,Changes,,Arrrows,In

Exclusives

$BTC

AAPL

AVGO

CLSK

DELL

LAES

MSTR

NVDA

PLTR

QBTS

QUBT

RGTI

SMCI

SOUN

TSLA

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 12월 벤징가 프로에서 가장 많이 검색된 주식들에 대한 정보이다. 현재 주가와 연초 대비 성과는 12월 31일 기준이며 배당금은 포함되어 있지 않았다. 11월의 데이터는 추적되지 않았다.

독점: 2024년 12월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 양자 컴퓨팅 주식은?

Nukkleus Inc

Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares are rallying some 24% to $4.07 during Monday&#8217;s session. The stock is now higher by 68% over the past week, despite a lack of any new company-specific news.
What To Know: Wolfspeed, a manufacturer of silicon carbide semiconductors used in electric vehicles and industrial applications, benefitted last week from broader strength in the semiconductor sector and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">renewed optimism</a> around economic growth.
Adding fuel to the rally, Wolfspeed has a short percentage of float of 64%, according to data from <a href="https://www.benzinga.com/pro/register?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=1FXaOQGh5vS1">Benzinga Pro</a>, raising the possibility that the stock is experiencing a short squeeze. In a short squeeze, investors who bet against the stock are forced to cover their positions as the price rises, creating further upward pressure.
Wolfspeed is also set to announce <a href="https://www.benzinga.com/quote/WOLF/earnings">third-quarter financial results</a>, confirmed for Thursday, May 8th in the after-market session.
Read Also: <a href="https://www.benzinga.com/25/04/45047782/boeing-stock-jumps-on-bernstein-upgrade-is-the-company-back-on-track">Boeing Stock Jumps On Bernstein Upgrade: Is The Company Back On Track?</a>
<h2 class="wp-block-heading">How To Buy WOLF Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Wolfspeed&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;Benzinga Pro, WOLF has a 52-week high of $30.86 and a 52-week low of $2.06.

WOLF

Wolfspeed (WOLF) Stock Is Up 24% Monday: What's Going On?

Maxim Group analyst Michael Diana maintains First Savings Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSFG#NASDAQ">FSFG</a>) with a Buy and raises the price target from $28 to $31.

Price Target

Analyst Ratings

FSFG

Maxim Group Maintains Buy on First Savings Financial, Raises Price Target to $31

A personal injury lawsuit was filed seeking damages against Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Kaiser Permanente, alleging their antipsychotic medications Risperdal and Zyprexa, along with generic forms, contributed to the plaintiff <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">developing breast cancer</a>.
The plaintiff claims that the defendants failed to adequately warn about the serious health risks associated with their drugs, which were marketed and sold for a wide range of uses beyond their original psychiatric indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report" rel="noreferrer noopener">Trump Administration Considers Lowering US Drug Prices To International Levels: Report</a>
Eli Lilly has manufactured, promoted and distributed Zyprexa since the drug received FDA approval in September 1996.
Both Zyprexa and Risperdal are categorized as second-generation, or atypical, antipsychotics.
Although introduced after 1990, these drugs are not necessarily safer or more effective than first-generation antipsychotics, according to the lawsuit filed last Monday.
The <a href="https://drive.google.com/file/d/1wpMX1c2VQ3m9TgMJiNuvHzSOg_adNiLx/view" target="_blank" rel="noreferrer noopener">complaint</a> further alleges that the drugmakers sought to expand their market by promoting these medications for milder conditions and off-label uses, such as treating attention deficit disorders in children, dementia in the elderly and mood stabilization.
Concerns about the connection between the defendants' drugs and breast cancer reportedly emerged early after their release.
These medications have been found to elevate prolactin levels—a hormone that, when abnormally increased, can result in hyperprolactinemia.
<ul>
<li>This condition is linked to several health complications, including a higher risk of breast cancer. </li>
<li>Despite early clinical trial warnings and subsequent epidemiological studies over the past two decades reinforcing the association, the lawsuit asserts that the defendants neither properly warned consumers nor accurately reported these risks.</li>
</ul>
Instead, the lawsuit claims, the companies actively downplayed the potential dangers by misrepresenting study results and omitting crucial information from drug labels. 
Allegations state that rather than alerting the public, the companies prioritized profits, continuing to promote these costly drugs over older, safer and less expensive alternatives.
As a result, the defendants are accused of profiting billions while exposing consumers to what the lawsuit describes as a potent carcinogen and tumor promoter.
Price Action: LLY stock is down 1.85% at $868.22, and JNJ stock is up 0.21% at $154.90 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45042630/why-is-cancer-drug-developer-revolution-medicines-stock-trading-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?</a></li>
</ul>

Biotech

Large Cap

Health Care

Legal

General

Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications

Investors are increasingly withdrawing from <a href="https://www.benzinga.com/topic/esg">ESG-themed investment vehicles</a>, with worldwide outflows from &#8220;sustainable&#8221; ETFs and mutual funds reaching a record $8.6 billion in the first quarter of this year.
Though America has been the initial epicenter of this ESG reversal, tremors are now being felt in Europe and Asia, casting doubt about the short-term sustainability of ESG strategies, even as under-the-radar long-term opportunities unfold.
According to the Financial Times, citing Morningstar figures, U.S. investors withdrew from sustainable funds for a tenth consecutive quarter. But in a dramatic change, European investors, long ESG&#8217;s most devoted followers, were net sellers for the first time on <a href="https://www.ft.com/content/9f425c25-4fc3-45de-bcc5-e9c75d6d14d3">record</a>, withdrawing $1.2 billion. Asia also experienced a decline in sustainable fund exposure.
Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45047236/etfs-last-week-funds-lead-the-charge-as-markets-stage-a-return-to-risk-on">ETFs Last Week: Funds Lead The Charge As Markets Stage A Return To Risk-On</a>
Despite the pullback, some ESG-themed ETFs, now available at discounted prices, may offer attractive long-term investment opportunities for investors willing to ignore the prevailing sentiment. Below are three ETFs, though affected by recent headwinds, that are worth consideration for the future:
<ul>
<li>iShares MSCI USA ESG Select ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUSA#NYSE">SUSA</a>): SUSA, which monitors U.S. companies with good ESG practice compared with industry peers, has experienced investor withdrawals as skepticism about ESG principles expands across the United States. The fund has witnessed a price erosion of almost 7% year-to-date. Still, SUSA&#8217;s emphasis on high-quality, sustainable business practice companies is a core strength, especially as corporate governance and environmental risks remain real risks to long-term profits.</li>
</ul>
<ul>
<li>iShares Global Clean Energy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLN#NASDAQ">ICLN</a>): ICLN, one of the leaders in the clean energy transition segment, has caught up in the general ESG retreat. However, as governments worldwide double down on decarbonization initiatives, clean energy remains an inevitable structural growth story. Recent price volatility may be unsettling, but for long-term investors, the sector's growth trajectory, driven by global policy mandates and technological innovation, remains intact. The fund has actually gained almost 3% this year so far, seemingly defying the pullout.</li>
</ul>
<ul>
<li>SPDR S&amp;P 500 ESG ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFIV#NYSE">EFIV</a>): This fund provides exposure to an ESG-screened variant of the S&amp;P 500, which shuns firms that engage in contentious businesses but remains sector-neutral. The fund has lost 8% of its value this year thus far. The current underperformance of the fund compared to its traditional peers is a reflection of the ESG chill in sentiment. Yet, EFIV&#8217;s strict discipline of offsetting ESG considerations with standard financials makes it well-placed to recover if regulatory certainty regarding ESG disclosures helps revive investor faith.</li>
</ul>
Looking Ahead: The wave of recent withdrawals, dramatic as it is, is perhaps in the end more a recalibration than a requiem for ESG investing. While Europe is <a href="https://www.benzinga.com/markets/esg/25/01/43393077/esg-investing-greenwashing-trend-or-profitable-strategy">tightening greenwashing rules</a> and arguing about the legitimacy of adding defense stocks to sustainable portfolios, the ESG scene is certainly changing, sometimes tumultuously, usually politically, but eventually tending toward increased transparency and realism.
To investors who can filter out the political noise and look to underlying trends, some ESG ETFs bruised by the latest backlash may bring not only virtue, but value.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45049512/eastmans-china-risk-jp-morgan-warns-trade-tensions-weighing-on-eastmans-growth-prospects">JPMorgan Cautions Trade Tensions Are Weighing On Eastman Chemical Growth Prospects</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

ETFs

EFIV

iShares S&P Global Clean Energy Index Fund

ICLN

SUSA

Top 3 ESG ETFs To Buy After Record Global Outflows: Long-Term Opportunities Amid The Backlash

V2X Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) announced Monday that it has <a href="/www.benzinga.com/pressreleases/25/04/n45035761/v2x-awarded-103-million-u-s-navy-contract-for-c-26-support-extending-legacy-as-a-readiness-multipl" target="_blank" rel="noreferrer noopener">secured a $103 million contract</a> from the U.S. Navy to deliver Contractor Logistics Support (CLS) services for the Navy&#8217;s C-26 aircraft fleet.
The agreement further cements V2X&#8217;s reputation as a trusted partner in ensuring operational aircraft readiness and mission success.
As part of the newly awarded contract, V2X will continue to provide critical support services, covering engineering, aircraft upgrades, maintenance, and modifications. This latest development reinforces the Navy&#8217;s faith in the company&#8217;s capabilities.
Jeremy C. Wensinger, President and CEO of V2X, expressed that the contract win underscores the Navy&#8217;s enduring confidence in V2X&#8217;s ability to maintain superior aircraft performance standards. &#8220;This award highlights the Navy&#8217;s continued confidence in V2X&#8217;s proven ability to deliver mission-capable aircraft with exceptional performance,&#8221; Wensinger said.
The contract, structured as a firm-fixed-price agreement, will officially commence in June 2025. It covers maintenance and support for eight C-26A/D aircraft located at four primary bases—one domestic and three international facilities.
Earlier in April, V2X secured a <a href="https://www.benzinga.com/pressreleases/25/04/n44681707/v2x-delivering-critical-support-to-u-s-missile-defense-and-space-surveillance-capabilities" target="_blank" rel="noreferrer noopener">$62 million contract</a> extension to maintain and enhance the COBRA DANE radar in Alaska, reinforcing its critical role in U.S. Space Force missile defense and space domain awareness through 2027.
<h2 class="wp-block-heading">VVX Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of V2X have an average 1-year price target of $62.25, representing an expected upside of 25.37%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on V2X, while 3 analysts have bullish ratings. The street high price target from Citizens Capital Markets is $80.0, while the street low from RBC Capital is $54.0.
Price Action: VVX shares are traded lower by 0.34% at $49.64 at the last check on Monday.
Photo by AU USAnakul via Shutterstock

Contracts

V2X Lands $103 Million Navy Aircraft Support Contract

Cryptocurrency markets are trading sideways on Monday, following a strong previous week that saw Bitcoin reclaim the $94,000 level.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$94,117</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$1,771</td>
<td>-1.8%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$146.87</td>
<td>-2.0%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.28</td>
<td>+1.5%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1761</td>
<td>-2.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.0000136</td>
<td>+01%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume up by 6.2% and daily active addresses down by 0.7%. </li>
<li>Coinglass data reports 115,648 traders were liquidated in the past 24 hours for $271.87 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45034209/bitcoin-could-hit-120000-in-q2-says-standard-chartereds-geoff-kendrick">Bitcoin Could Hit $120,000 In Q2, Says Standard Chartered&#8217;s Geoff Kendrick</a></li>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/04/45039498/sec-approves-proshares-xrp-futures-etfs-xrp-price-surges-ahead-of-launch">SEC Approves ProShares XRP Futures ETFs: XRP Price Surges Ahead Of Launch</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45039243/xrp-is-the-top-altcoin-bet-10x-research">XRP Is The Top Altcoin Bet: 10x Research</a></li>
<li><a href="https://www.benzinga.com/25/04/45046221/pudgy-penguins-coin-pengu-outperforms-dogecoin-shiba-inu-with-123-weekly-gain">Pudgy Penguins Coin PENGU Outperforms Dogecoin, Shiba Inu With 123% Weekly Gain</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45048427/watch-this-bitcoin-indicator-to-know-if-a-run-to-100000-is-coming">Watch This Bitcoin Indicator To Know If A Run To $100,000 Is Coming</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Virtuals Protocol (CRYPTO: VIRTUAL)</td>
<td>&nbsp;$1.36</td>
<td>+25.6%</td>
</tr>
<tr>
<td>Monero (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xmr/usd">XMR</a>)</td>
<td>&nbsp;$257.21</td>
<td>+11.8%</td>
</tr>
<tr>
<td>Bittensor (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>)</td>
<td>&nbsp;$372.71</td>
<td>+6.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Prominent trader &#8220;Inmortal&#8221; says the most likely scenario for Bitcoin, in case it holds the $90,000 level, is a period of sideways trading, followed by another uptrend in June.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The most likely scenario if we hold above 90k<a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/z4jHBmJkNS">pic.twitter.com/z4jHBmJkNS</a>
&mdash; Inmortal (@inmortalcrypto) <a href="https://twitter.com/inmortalcrypto/status/1916906045508661371?ref_src=twsrc%5Etfw">April 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Jelle <a href="https://x.com/CryptoJelleNL/status/1916880982923465103">opines</a> that as long as Bitcoin holds above $94,000, it could test the $100,000 level in the next days.
Prominent analyst Kevin highlighted the golden pocket level around $95,300 as a key resistance to be overcome. Bitcoin has been trading around this level for several days.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45017648/bitcoin-climbs-12-on-the-week-as-traders-eye-run-to-100000">Bitcoin Climbs 12% On The Week As Traders Eye Run To $100,000</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$ETH

$SHIB

$SOL

$TAO

$XMR

$XRP

Bitcoin Ethereum XRP Dogecoin Hold Firm After Last Week's Rally: What's Next

As Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) showed in its <a href="https://www.benzinga.com/news/25/04/45039495/dominos-pizza-q1-operating-margin-shrinks-as-lower-income-consumers-feel-the-pinch">latest earnings report</a>, even America's favorite comfort food is not immune to the chill of a cooling economy. High inflation and jittery consumer sentiment, spooked by erratic trade policies, pulled down U.S. same-store sales by 0.5% on-year in the first quarter — a surprise miss against expectations.
Yet, all is not burnt crust and bad news. Domino&#8217;s surpassed earnings estimates with an EPS of $4.33, compared to $3.58 in the same quarter last year.
Smart tech investments by Domino&#8217;s, such as AI-based order preparation and their AnyWare platform, are likely to keep holding investor faith. On top of that, its new agreement with DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>), which is launching nationwide in May, Domino&#8217;s has laid the groundwork for a possible comeback in the second half of the year.
This resiliency might make <a href="https://www.benzinga.com/etfs">ETFs holding restaurant stocks</a> an excellent opportunity for investors seeking to ride out economic volatility. Funds exposed to names such as Domino&#8217;s, McDonald&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), and Chipotle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)—all firms focusing on tech development and value-for-money strategies—may provide a defensive yet lively play.
The following are three ETFs that investors may consider adding to their menu:
AdvisorShares Restaurant ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EATZ#NYSE">EATZ</a>)
EATZ is the sole pure-play restaurant ETF in the U.S. market, providing direct exposure to quick-service behemoths such as Domino&#8217;s, McDonald&#8217;s and Chipotle.
With a diversified basket in fast food, casual dining and coffee chains, EATZ is for those who think Americans will hold on to their comfort food, recession or not.
Domino&#8217;s is one of its top holdings, making it a natural choice for those wagering on pizza&#8217;s staying power.
However, EATZ has a reasonably small asset base, which may result in thinner liquidity. This makes it best suited for investors with a slightly higher tolerance for volatility.
Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)
XLY provides more extensive exposure to consumer discretionary names, with heavyweight positions in Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), but also brings in big restaurant players such as McDonald&#8217;s and Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
It&#8217;s less restaurant-intensive but gives more diversification to investors who desire dining stocks without going &#8220;all in&#8221; on the group.
During turbulent markets, the power of familiar names can be like economic comfort food, reassuring but with less risk.
Invesco Dynamic Leisure and Entertainment ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEJ#NYSE">PEJ</a>)
PEJ follows U.S. leisure and entertainment companies — including large restaurant chains.
It tilts toward companies poised for consumer discretionary spending, picking up both restaurants and entertainment spots.
US Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) and others typically have a spot on its list, surfing trends such as value-based dining and convenience-optimized ordering like DoorDash.
PEJ&#8217;s high-momentum selection strategy aims to pick up companies with good fundamentals and momentum, making it a good choice in turbulent economic climates.
It is interesting to note that the <a href="https://www.benzinga.com/topic/warren-buffett">recent action by Warren Buffett&#8217;s</a> Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) to <a href="https://www.benzinga.com/content/44975325/2-smart-investments-to-follow-warren-buffetts-lead">raise its stake in Domino&#8217;s in Q3 2024</a>, just ahead of the latest tariff-led market volatility further supports the notion: even when the economy is shaken like a pizza, innovation, value and customer loyalty can make the dough keep coming.
For ETF investors, this could be the time to try restaurant-themed or consumer-discretionary funds that serve up a full plate of durability. After all, when pocketbooks get tight, Americans might skip the gourmet meal — but they&#8217;ll still call for a $10 pizza, maybe with extra cheese.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45047236/etfs-last-week-funds-lead-the-charge-as-markets-stage-a-return-to-risk-on">ETFs Last Week: Funds Lead The Charge As Markets Stage A Return To Risk-On</a></li>
</ul>
Photo: Shutterstock

Earnings Misses

AMZN

DASH

EATZ

PowerShares ETF Leisure & Entertainment Port

SBUX

USFD

Select Sector SPDR-Consumer Discretionary

Domino's Pizza Earnings Miss: 3 ETFs That Could Still Deliver Tasty Returns In 2025

Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This represents the third clinical study evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting, with outcomes reported in mismatch repair–proficient (pMMR/MSS) and mismatch repair–deficient (dMMR/MSI-H) solid tumors. These findings include the first reported outcomes with BOT/BAL outside colorectal cancer in the neoadjuvant setting.

AGEN

Agenus: Initial Results From NEOASIS Show BOT/BAL Efficacy In Neoadjuvant Setting Across Multiple MSS And MSI-H Solid Tumors

We've been getting&nbsp;<a href="https://www.tker.co/p/economic-data-earnings-results-ambiguous">ambiguous signals in the economic data</a>.
On one hand, the soft, sentiment-oriented data has been disappointing. The&nbsp;<a href="https://www.sca.isr.umich.edu/">University of Michigan</a>&nbsp;and the&nbsp;<a href="https://www.conference-board.org/topics/consumer-confidence">Conference Board's</a>&nbsp;surveys of consumer confidence have turned sharply lower in recent months. The&nbsp;<a href="https://www.nfib.com/wp-content/uploads/2025/04/NFIB-SBET-Report-March-2025.pdf">NFIB's Small Business Optimism index</a>&nbsp;has tanked. Sentiment among&nbsp;<a href="https://www.apolloacademy.com/corporate-confidence-declining/">CEOs and CFOs</a>&nbsp;has turned south. Purchasing managers at&nbsp;<a href="https://www.ismworld.org/globalassets/pub/research-and-surveys/rob/pmi/t4rf202503pmi.pdf">manufacturing</a>&nbsp;and&nbsp;<a href="https://www.ismworld.org/globalassets/pub/research-and-surveys/rob/nmi/5tagrob202503svcs.pdf">services</a>&nbsp;firms have also become increasingly cautious. And it's all because of the Trump administration's volatile position on tariffs — which most people&nbsp;<a href="https://www.tker.co/p/wall-street-brief-explanation-tariffs">agree are net negative for the economy</a>.
On the other hand, the hard data, which reflects actual activity, has been strong. <a href="https://www.tker.co/i/161227758/review-of-the-macro-crosscurrents">Retail sales</a> hit a record high in March, and weekly card spending data suggest that strength has continued into April. Durable goods orders and shipments continue at elevated levels. Meanwhile, key labor market metrics including job creation, unemployment, and claims for unemployment insurance continue to trend at levels associated with economic expansion.
This narrative of contradictions is illustrated nicely in this chart from Goldman Sachs, which shows how soft data has been surprising to the downside while hard data has been surprising to the upside. In other words, sentiment has been weaker than expected while realized activity has been stronger than expected.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F50658b33-5637-46a3-8c08-631f0ee9807a_1746x1288.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F50658b33-5637-46a3-8c08-631f0ee9807a_1746x1288.png" alt="" title="" /></a><figcaption class="wp-element-caption">The hard data has been surprisingly good despite the soft data being surprisingly bad. (Source: Goldman Sachs)</figcaption></figure>
Renaissance Macro's Neil Dutta wrote about these "data discontinuities" in his April 21 note.
"It's probable that much of the recent upside surprises in hard data reflect pulling forward activity in the anticipation of tariffs," Dutta wrote. "Consumers pulled forward auto sales and consumption on other household durables, as an example. Firms likely pulled forward some orders too. That likely gives the veneer of strength in the recent high-frequency dataflow."
During much of the economic expansion that began in 2020, it's paid off to focus on what&nbsp;<a href="https://www.tker.co/p/october-retail-sales-strong-sentiment-inflation">consumers</a>&nbsp;and&nbsp;<a href="https://www.tker.co/p/weekly-macro-soft-vs-hard-data">businesses</a>&nbsp;did (i.e., the hard data) over what they said (i.e., the soft data). The Federal Reserve&nbsp;<a href="https://www.federalreserve.gov/econres/notes/feds-notes/tracking-consumer-sentiment-versus-how-consumers-are-doing-based-on-verified-retail-purchases-20250424.html">just published research</a>&nbsp;explaining this phenomenon.
But in a world where many are&nbsp;<a href="https://www.tker.co/p/sales-pull-forward-frontrunning-tariffs">aware of the inflationary risks of new tariffs</a>, this&nbsp;<a href="https://www.tker.co/p/economic-data-earnings-results-ambiguous">pull-forward of sales</a>&nbsp;comes with two issues: 1) it masks what may be a much&nbsp;<a href="https://www.tker.co/p/hot-economic-charts-that-cooled">weaker underlying economy</a>, and 2) we could get&nbsp;<a href="https://www.tker.co/i/158036475/brace-for-payback">depressed sales in the future</a>&nbsp;when these pulled-forward sales would've normally occurred.
"[R]ecent hard data in the U.S., mostly for March, are overstating activity and it's worth noting that conditions were not especially strong to begin with," Dutta added. "The collapse across a range of survey-based measures of activity suggest that actual activity will continue to slowdown, in a potentially abrupt manner. Recession may already be here."
<h2 class="wp-block-heading">The big picture &#x1f5bc;&#xFE0F;</h2>
We'll only know with the benefit of hindsight whether or not we're in a recession or going into a recession.
However, we know that&nbsp;<a href="https://www.tker.co/p/hot-economic-charts-that-cooled">the economy had been cooling</a>&nbsp;and that the threat of tariffs&nbsp;<a href="https://www.tker.co/p/stock-market-history-with-recessions">increased the risk of recession</a>.
Importantly, as long term investors, we should understand that&nbsp;<a href="https://www.tker.co/p/stock-market-history-with-recessions">recessions</a>&nbsp;and&nbsp;<a href="https://www.tker.co/p/bear-markets-in-context">market downturns</a>&nbsp;will happen as you build wealth with stocks.
The economy has been in expansion&nbsp;<a href="https://www.tker.co/i/135828032/most-actual-news-about-the-economy-and-the-stock-market-isnt-bad">about 80% of the time</a>. Similarly, stocks have been in a bull market&nbsp;<a href="https://www.tker.co/i/135828032/most-actual-news-about-the-economy-and-the-stock-market-isnt-bad">about 80% of the time</a>. Maybe we're currently going through an unpleasant period that has historically occurred about 20% of the time.
<h4 class="wp-block-heading">&#x2A;&#x2A;</h4>

Equities

Econ #s

Opinion

Ambiguous Signals In Economic Data

On Friday, AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported an adjusted EPS of $2.46, up 6.5% year over year and beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.38</a>.
The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a reported basis (+9.8% on an operational basis), beating the <a target="_blank" href="https://www.benzinga.com/25/04/45011116/abbvie-q1-earnings-come-ahead-of-expectations-ceo-says-well-positioned-for-long-term" rel="noreferrer noopener">consensus of $12.92 billion</a>.
It reported adjusted earnings per share of $2.46, beating the street view of $2.38.
BMO Capital Markets writes that every quarter seems to tell the same story. Analysts think they&#8217;ve accurately factored in Skyrizi and Rinvoq&#8217;s growth, only for AbbVie to outperform expectations once again.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44937940/abbvies-pipeline-may-be-a-2026-story-but-analyst-likes-the-setup-now" rel="noreferrer noopener">AbbVie&#8217;s Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now</a>
In the first quarter of 2025, Skyrizi and Rinvoq beat consensus estimates by 7% and 8%, respectively.
<ul>
<li>Skyrizi sales increased 70.5% (+72%) to $3.425 billion.</li>
<li>Rinvoq sales reached $1.72 billion, an increase of 57.2% (+59.7%).</li>
</ul>
&#8220;While we are still carefully watching the launch of Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Tremfya as it begins to build momentum, 1Q25 demonstrated the prowess of AbbVie&#8217;s commercial contracting team again, pushing us to again revise our estimates higher for the two products. With Skyrizi now capturing 1 in 3 in place UC patients, we highlight that the company&#8217;s I&amp;I portfolio appears poised to continue growing through more significant Humira erosion,&#8221; analyst Evan David Seigerman writes.
Seigerman writes that AbbVie appears well-positioned to manage through Humira&#8217;s U.S. patent loss. With the acquisition of ImmunoGen and Cerevel, AbbVie is well-positioned to capitalize on Elahere&#8217;s growth and key readouts for emeraldine/tavapadon.
Vyalev was a minor contributor to AbbVie&#8217;s overall beat, but BMO Capital writes that investors may be underappreciating its growth and upside. With Medicare reimbursement not yet in place, the analyst sees more upside to analyst estimates over the coming quarters. Advancements with Vyalev appear to pair well with Cerevel&#8217;s tavapadon, which could also be commercialized in 2026, meaningfully expanding the company&#8217;s Parkinson&#8217;s portfolio.
Vyalev is&nbsp;a prescription medication used to treat motor fluctuations in adults with advanced Parkinson&#8217;s disease.
<ul>
<li>BMO maintains the Outperform rating and a <a href="https://www.benzinga.com/quote/ABBV/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $215</a>.</li>
<li>Morgan Stanley maintains AbbVie with an Overweight, raising the price target from $241 to $250.</li>
<li>Evercore ISI Group keeps the Outperform rating for AbbVie, raising the price target from $204 to $205.</li>
</ul>
Price Action: ABBV stock is up 2.54% at $190.79&nbsp;at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44950727/bristol-myers-cobenfy-falls-short-on-primary-endpoint-in-phase-3-schizophrenia-trial" target="_blank" rel="noreferrer noopener">Bristol Myers&#8217; Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Guidance

ABBV

AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst

<a href="https://www.bloomberg.com/news/articles/2025-04-28/ups-in-talks-with-startup-figure-ai-to-deploy-humanoid-robots" title="https://www.bloomberg.com/news/articles/2025-04-28/ups-in-talks-with-startup-figure-ai-to-deploy-humanoid-robots">https://www.bloomberg.com/news/articles/2025-04-28/ups-in-talks-with-startup-figure-ai-to-deploy-humanoid-robots</a>

'UPS In Talks With Startup Figure AI To Deploy Humanoid Robots' - Bloomberg News

Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>)&nbsp;is <a target="_blank" href="https://www.benzinga.com/topic/sony" rel="noreferrer noopener">weighing spinning off</a> its semiconductor unit Sony Semiconductor Solutions Corp.
The spinoff and listing of the&nbsp;semiconductor unit&nbsp;may occur by 2025.
Sony is considering distributing most of its holding in the chip business and may retain a minority holding after the spinoff, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-28/sony-is-said-to-mull-chip-spinoff-that-loeb-called-for-years-ago?sref=TBDibEcD" rel="noreferrer noopener">reported</a> Monday, citing unnamed sources familiar with the matter.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44787792/sony-raises-ps5-prices-in-some-countries-by-up-to-25-in-anticipation-of-tariffs" rel="noreferrer noopener">Sony Raises PS5 Prices In Some Countries By Up To 25% In Anticipation Of Tariffs</a>
Sony is also planning to spin off <a href="https://www.benzinga.com/news/23/05/32459765/sony-shares-are-surging-premarket-company-eyes-sony-financial-arm-ipo" target="_blank" rel="noreferrer noopener">its financial arm</a>, Sony Financial Group Inc, in line with investor Dan Loeb's plans to unlock value.
Sony reported <a target="_blank" href="https://www.benzinga.com/25/02/43700230/sony-q3-earnings-beats-expectations-raises-outlook-as-ps5-sales-and-streaming-revenues-climb" rel="noreferrer noopener">fiscal third-quarter</a> 2024 consolidated sales&nbsp;growth&nbsp;of 18% to $28.97 billion (4.41 trillion Japanese yen), topping the&nbsp;analyst consensus estimate of&nbsp;$23.78 billion.&nbsp;EPS of $0.41 (61.82 yen) beat the&nbsp;analyst consensus estimate of $0.30.
Consolidated operating income rose by 1% to ¥469.3 billion. Game &amp; Network Services operating income climbed 37%&nbsp;to&nbsp;¥118.1 billion. Music operating income increased by 28%&nbsp;to ¥97.4 billion. Pictures operating income declined by 18% to ¥34.0 billion. Entertainment, Technology, &amp; Services operating income remained flat at ¥77.1 billion.&nbsp;Imaging &amp; Sensing Solutions operating income declined 2%&nbsp;to ¥97.5 billion. Financial Services operating income decreased by 40% to ¥46.4 billion.
Sony expects fiscal 2024 sales of $88.00 billion or ¥13.20 trillion versus&nbsp;the&nbsp;$81.59 billion consensus.&nbsp;
Recently, Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) announced a&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44828811/intel-growth-challenges-are-not-over-despite-altera-stake-sale-analyst" rel="noreferrer noopener">51% stake sale</a>&nbsp;of its programmable chip business, Altera, to private equity firm Silver Lake Management for $4.46 billion, valuing Altera at $8.75 billion. Intel originally acquired Altera for $16.7 billion in December 2015.
Price Action: SONY stock traded higher by 0.6% to $25.11 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43052360/sony-cancels-two-live-service-games-stays-committed-to-long-term-monetization" target="_blank" rel="noreferrer noopener">Sony Cancels Two Live-Service Games, Stays Committed to Long-Term Monetization</a></li>
</ul>
Photo: testing/Shutterstock

Media

INTC

Sony Group Corporation American Depositary Shares

SONY

What's Pushing Sony To Consider A Semiconductor Spinoff?

Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares are trading lower Monday. Oppenheimer analyst Jason Helfstein maintained an Outperform rating on Amazon but lowered the price target from $260 to $220.
What To Know: Helfstein reduced estimates ahead of the company&#8217;s upcoming earnings report, citing uncertainty around the impact of tariffs on the e-commerce industry.
He believes third-quarter results will be hit the hardest, as Amazon sellers still have inventory purchased before tariffs took effect.
Amazon CEO Andy Jassy told CNBC some sellers are buying inventory ahead of time, with consumers also making purchases before expected price increases. Sellers are likely to pass higher tariff costs onto consumers, although no major shifts in behavior have been seen yet.
Helfstein lowered overall revenue estimates by 2% for fiscal-year 2025 and 1% for fiscal-year 2026, matching the reductions to North America forecasts. He also cut international revenue projections by 2% and Amazon Web Services revenue by 1%.
The analyst also cut EBIT estimates, expecting total EBIT to fall 19% in fiscal-year 2025 and 14% in fiscal-year 2026. North America EBIT is projected to drop 49% in 2025 and 35% in 2026, while International EBIT and Amazon Web Services EBIT are expected to decline 2% and 1%, respectively.
See Also: <a href="https://www.benzinga.com/news/25/04/45049101/toyota-eyes-major-shakeup-with-42-billion-offer-for-toyota-industries">Toyota Eyes Major Shakeup With $42 Billion Offer For Toyota Industries</a>
AMZN Price Action: At the time of writing, Amazon shares are trading 1.10% lower at $186.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

Oppenheimer's Helfstein Cuts Amazon Price Target To $220 On Tariff Concerns

There's little doubt the tariff wars have taken a toll on Americans' investment portfolios. And with the markets still in disrepair, nobody knows when stocks will stabilize.
"The situation is volatile, to say the least," said Doug Carey, a financial advisor at WealthTrace, a retirement planning consumer software company. "President Trump has the final word on how much tariffs will cost because he is using emergency powers, citing the International Emergency Economic Powers Act (IEEPA), passed in 1977. These moves may be struck down in court, but for now, he can use them."
To peg a reasonable timeframe, Benzinga reached out to select market experts for their views on a permanent "ceasefire" in the tariff wars, which could help calm anxious investors and encourage them to return to the market.
Here's what they had to say on when the markets will come back to sanity.
Doug Carey: There will likely be several signs that the market is set to rebound after the tariff issue is settled &#8211; or at least stabilized. "Look for the stock market to rise substantially and for the dollar to strengthen," Carey said. "Gold, which has increased over 25% this year due to the fear of a larger trade war, will do poorly if the tariff drama ends."
Carey said technology stocks were hurt the most by the fear of a trade war. "For those who believe that there will be an end to this drama soon, the tech sector is a good place to invest," he added.
Javier Palomarez, founder &amp; CEO of the United States Hispanic Business Council: "The clearest signal would be a statement from the Trump Administration that the tariffs are being walked away from, as a result of negotiations or whatever the case may be," Palomarez said. "However, it's worth noting that declining stocks also represent robust opportunities. Ideally, one would purchase their investments just before such a statement."
Palomarez advises investors to be vigilant about watching tariff trends – you don't want to miss the market rebound.
"If investors sold their stock at the low, it's critical to purchase it back before the market fully reacts to the signal that everything is clear, especially if you plan on investing in stocks that are vulnerable to future tariffs and regulations," Palomarez added. "Some investors may want to consider index funds or stocks in industries that are insulated from such rapid changes and regulatory uncertainty."
Chuck Zhang, CFO of PolyFlow, a decentralized payments company in Fair Lawn, N.J.: Last week, President Trump hinted at a possible shift in his trade stance with China, suggesting that the steep tariffs on Chinese imports will be substantially reduced. "His comments signal a softening in tone following weeks of escalating rhetoric and retaliatory measures that had driven tariffs on Chinese goods to over 145%," Zhang said. "While this would be a positive development in terms of de-escalation, the overarching trade policy remains assertive, contributing to the recent market volatility."
Zhang said he would advise investors to monitor several variables. "We're looking at a definitive resolution or rollback of tariffs; sustained rallies in equity markets, drops in the VIX volatility index, especially in sectors previously affected by tariffs; and overall improvements in global trade volumes, manufacturing indices, and corporate earnings," he said.
Investors should simultaneously evaluate asset allocations to achieve alignment with their long-term financial goals, considering a diversified mix of equities, bonds and other assets.​ "Then, as a general rule, prioritize investments in companies with strong balance sheets and consistent earnings," Zhen advised.
Jeff Weniger, head of equity strategy at the asset management firm Wisdom Tree: Weniger suspects the tariff issue is at the stage where the most aggressive bargaining chips are being methodically pulled off the table. "For example, India and Japan are priced at 84% and 77% probabilities, respectively, of coming to a trade deal with the Trump administration by July," he said. "Though other countries' probabilities are priced lower (China is 42%), this is a far cry from some of the intense pessimism that was being priced in earlier this summer."
For now, though, the worst of the drama is likely over. "The peak risk in markets was the 145% tariff on China, with similar reciprocity," Weniger added. "Those figures have been coming down for a few weeks, as has the tone of commentary from both the White House and Beijing."
Wenger also advised investors to keep an eye on volatility gauges such as the VIX index. "That index headed north of 60 on April 7th, a level of fear akin to readings that registered right after 9/11 and amid the bank and insurance company failures of late 2008," he added. "Fear levels on that order often precipitate heady gains in stocks."
<h2 class="wp-block-heading">Play The Tariff Game To Your Advantage</h2>
Other market experts say there is no clear sign that indicates the end of the tariff drama.
"This situation is not like a typical economic cycle with predictable patterns," said Julia Khandoshko, CEO at Mind Money, an international brokerage firm. "Instead, it resembles a new phase in global economics — what might one day be known as the &#8216;Tariff Wars of the 21st Century.'&#8221;
Khandoshko believes investors shouldn't wait for an obvious turning point, because one may never come. "Rather than looking for a specific event or announcement, they should integrate tariff risks into their long-term strategy," she said. "This means evaluating how particular companies might be impacted if tariffs are imposed on their goods or services."
Others agree, adding that tampering with the nation's Treasury market is a bad idea going forward.
"There may not be an &#8216;all clear&#8217; signal on tariffs because of politics," said David Russell, global head of market strategy at TradeStation Group in Chicago. "Officials may quietly backpedal on them without a lot of publicity. This crisis started with a bang, but it might end with a whimper."
Russell also offers a "lessons learned" factor for investors to absorb when the tariff-related carnage is over.
"Investors have learned that the bond market matters," he noted. "Our system relies on a functioning Treasury market, which requires a degree of foreign participation. Undermining that system threatens the foundation of the stock market and the entire economy."
<h2 class="wp-block-heading">Turn Earnings Reports Into Trading Opportunities</h2>
Over 160 companies reported earnings recently, including Walmart, Alibaba, and Rivian. Benzinga Edge gives you instant access to earnings surprises, market-moving insights, and expert-driven strategies to act fast. Unlock Your Edge <a href="https://www.benzinga.com/premium/ideas/benzinga-edge">HERE</a>
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Interview

How You'll Know When Tariff Troubles Are Finally Over

PBYI

Puma Biotechnology Presents Clinical Data Of Phase I Trial Of trastuzumab deruxtecan In Combination With Neratinib In Solid Tumors With HER2 Alterations At AACR 2025

The <a href="https://www.benzinga.com/general/sports/25/04/44990571/2025-nfl-draft-how-to-watch-betting-odds-will-record-first-round-happen">2025 NFL Draft</a> is complete, and attention turns to how rookies will factor into their new team's depth charts for the next season.
Here's a look at the early Rookie of the Year betting odds.
Offensive Rookie of the Year: The quarterback position remains one of the most important in the NFL and last year's 2024 NFL Draft saw Jayden Daniels win the offensive rookie of the year after being one of a record-tying six quarterbacks drafted <a href="https://www.benzinga.com/general/sports-betting/24/04/38501129/2024-nfl-draft-recap-quarterbacks-wide-receivers-detroit-set-records-who-will-win-rookie-o">in the first round.</a>
In the 2025 NFL Draft, there were only two quarterbacks drafted in the first round. Cam Ward is the number one overall pick by the Tennessee Titans. Jaxson Dart was selected later in the first round by the New York Giants.
In the last two seasons, the second overall pick and quarterback selected second in the draft has won the Rookie of the Year. Daniels won last year and C.J. Stroud won the year before that.
While Dart went later in the first round, he would fit that current trend of being the second quarterback drafted and the best rookie. Dart isn't expected to start in the 2025 NFL season with Russell Wilson brought in to lead the way, but who knows what will happen.
The big storyline in the 2025 NFL Draft was Colorado quarterback Shedeur Sanders falling out of the first round and dropping down to the fifth round where he was taken by the Cleveland Browns who now have five quarterbacks competing for the starting role including Sanders and fellow 2025 NFL Draft pick Dillon Gabriel, taken 94th overall in the third round.
Sanders will have a chip on his shoulder after falling in the draft, but given the Browns' depth at the position, he may not see the field next season.
Here are the current betting odds for the 2025 Offensive Rookie of the Year from DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>):
<ul>
<li>Ashton Jeanty (Raiders, RB): +200</li>
<li>Cam Ward (Titans, QB): +230</li>
<li>Travis Hunter (Jaguars, WR): +750</li>
<li>Tyler Shough (Saints, QB): +1,200</li>
<li>Tetairoa McMillan (Panthers, WR): +1,400</li>
<li>Omarion Hampton (Chargers, RB): +1,600</li>
<li>Quinshon Judkins (Browns, RB): +1,800</li>
<li>Shedeur Sanders (Browns, QB): +1,900</li>
<li>TreVeyon Henderson (Patriots, RB): +2,000</li>
<li>Colston Loveland (Bears, TE): +2,200</li>
</ul>
Of the top betting favorites, Shough, Judkins, Sanders and Henderson were all drafted after the first round. Over the last 10 seasons, the offensive rookie of the year has come from the first round eight times, with Alvin Kamara (second round) and Dak Prescott (fourth round) the exceptions.
Shough could be the immediate starter for the Saints and get a chance to compete for the award.
Another trend to watch will be the tight end position with Brock Bowers (Raiders) placing second in voting last year after breaking several records for the position. No tight end has ever won offensive rookie of the year.
Tight ends Loveland and Tyler Warren (+3,000) were first round picks who will be likely day one starters and could compete for the award as long as no quarterback has a huge season.
In the last 10 seasons, there have been five quarterbacks to win the award, along with three running backs and two wide receivers.
Travis Hunter is the other topic to watch as he is a two-way player and expected to play both wide receiver and cornerback for the Jaguars, who moved up to take him in the 2025 draft.
Fanduel, owned by Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), also has betting lines of Hunter winning either rookie of the year award at odds of +440 and odds of him winning both offensive and defensive rookie of the year at +5,000.
With Hunter playing both sides of the ball, it may hurt his chances of winning either award, while playing both positions likely helped him winning the Heisman Trophy, which went to the best overall college football player for both offense and defense.
Across the last 10 drafts, the second overall pick won five Rookie of the Year awards for either offense or defense. That trend that could favor Hunter.
Ahead of the 2024 NFL season, first overall pick QB Caleb Williams (Bears) was the early favorite, while Daniels was listed with odds of +650.
Read Also: <a href="https://www.benzinga.com/general/sports/24/12/42521231/travis-hunter-wins-heisman-will-he-be-1-pick-in-2025-nfl-draft-what-betting-odds-history-show">Travis Hunter Wins Heisman, Will He Be #1 Pick In 2025 NFL Draft? What Betting Odds, History Show</a>
Defensive Rookie of the Year: On the other side of the ball, the defensive rookie of the year has been dominant by players taken in the first round.
Of the last 10 NFL Drafts, nine of the defensive rookie of the years came from the first round with the 19th pick or earlier. The one exception was a player taken 36th overall in the second round.
The defensive rookie of the year has been fairly evenly split by position with three linebackers winning, three defensive ends winning, three cornerbacks winning and one defensive lineman winning.
Here are the betting favorites for defensive rookie of the year at DraftKings:
<ul>
<li>Abdul Carter (Giants, Edge/DE): +250</li>
<li>Travis Hunter (Jaguars, CB): +750</li>
<li>Mykel Williams (49ers, Edge/DE): +900</li>
<li>Jalon Walker (Falcons, LB): +900</li>
<li>Jihaad Campbell (Eagles, LB): +1,200</li>
<li>Mason Graham (Browns, DT): +1,400</li>
<li>Shemar Stewart (Bengals, Edge/DE): +1,600</li>
<li>Mike Green (Ravens, Edge/DE)): +1,600</li>
</ul>
All the favorites were first round picks, outside of Green, who slid to the second round.
Last year, Jared Verse started the season ranked fourth at +1,100 odds after the NFL Draft before going on to win the defensive rookie of the year. Cater, who was considered the top prospect in the draft by some experts, is likely to stay the defensive favorite until the season begins.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43608426/super-bowl-lix-rematch-again-sportsbooks-list-eagles-chiefs-as-top-favorites-for-super-bowl-lx">Super Bowl LIX Rematch Again? Sportsbooks List Eagles, Chiefs As Top Favorites For Super Bowl LX</a></li>
</ul>
Image: Shutterstock

Sports Betting

Sports

DKNG

FLUT

NFL Rookie Of The Year Betting Odds: Shedeur Sanders Payout, Travis Hunter To Win Both Awards?

JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect JetBlue Airways to report an earnings per share (EPS) of $-0.62.
Investors in JetBlue Airways are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.09, leading to a 1.5% increase in the share price the following trading session.
Here's a look at JetBlue Airways's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.30</td>
<td>-0.25</td>
<td>-0.11</td>
<td>-0.52</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.16</td>
<td>0.08</td>
<td>-0.43</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-7.000000000000001%</td>
<td>-4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866977_0.png" alt="eps graph" />
<h3>Market Performance of JetBlue Airways's Stock</h3>
Shares of JetBlue Airways were trading at $3.88 as of April 25. Over the last 52-week period, shares are down 28.7%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on JetBlue Airways</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on JetBlue Airways.
Analysts have provided JetBlue Airways with 8 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $4.44, suggesting a potential 14.43% upside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Allegiant Travel, Frontier Group Holdings and Sun Country Airlines, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Allegiant Travel, with an average 1-year price target of $64.43, suggesting a potential 1560.57% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Frontier Group Holdings, with an average 1-year price target of $7.02, suggesting a potential 80.93% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sun Country Airlines, with an average 1-year price target of $14.5, suggesting a potential 273.71% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Allegiant Travel, Frontier Group Holdings and Sun Country Airlines, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>JetBlue Airways</td>
<td>Neutral</td>
<td>-2.06%</td>
<td>$426M</td>
<td>-1.67%</td>
</tr>
<tr>
<td>Allegiant Travel</td>
<td>Neutral</td>
<td>2.73%</td>
<td>$115.95M</td>
<td>-18.10%</td>
</tr>
<tr>
<td>Frontier Group Holdings</td>
<td>Neutral</td>
<td>12.46%</td>
<td>$83M</td>
<td>9.19%</td>
</tr>
<tr>
<td>Sun Country Airlines</td>
<td>Neutral</td>
<td>6.05%</td>
<td>$58.63M</td>
<td>2.39%</td>
</tr>
</tbody>
</table>

Key Takeaway:
JetBlue Airways ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is in the middle for Return on Equity.
<h3>About JetBlue Airways</h3>
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic &amp; Canada segment.
<h3>JetBlue Airways's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: JetBlue Airways's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.06%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: JetBlue Airways's net margin excels beyond industry benchmarks, reaching -1.93%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): JetBlue Airways's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.67%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): JetBlue Airways's ROA excels beyond industry benchmarks, reaching -0.26%. This signifies efficient management of assets and strong financial health.
Debt Management: JetBlue Airways's debt-to-equity ratio surpasses industry norms, standing at 3.46. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/JBLU/earnings">To track all earnings releases for JetBlue Airways visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JBLU

JetBlue Airways's Earnings Outlook

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Sage Therapeutics to report an earnings per share (EPS) of $-0.99.
The market awaits Sage Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.20 in the last quarter, leading to a 0.42% drop in the share price on the following day.
Here's a look at Sage Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.36</td>
<td>-1.53</td>
<td>-1.66</td>
<td>-1.65</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.56</td>
<td>-1.53</td>
<td>-1.70</td>
<td>-1.80</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-24.0%</td>
<td>-11.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866969_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Sage Therapeutics were trading at $7.79 as of April 25. Over the last 52-week period, shares are down 44.51%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Perspectives on Sage Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Sage Therapeutics.
A total of 4 analyst ratings have been received for Sage Therapeutics, with the consensus rating being Neutral. The average one-year price target stands at $9.5, suggesting a potential 21.95% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Regenxbio, Precigen and MeiraGTx Hldgs, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Regenxbio, with an average 1-year price target of $32.0, suggesting a potential 310.78% upside.</li>
<li>Analysts currently favor an Buy trajectory for Precigen, with an average 1-year price target of $6.0, suggesting a potential 22.98% downside.</li>
<li>Analysts currently favor an Buy trajectory for MeiraGTx Hldgs, with an average 1-year price target of $24.5, suggesting a potential 214.51% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Regenxbio, Precigen and MeiraGTx Hldgs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sage Therapeutics</td>
<td>Neutral</td>
<td>-83.56%</td>
<td>$11.33M</td>
<td>-18.84%</td>
</tr>
<tr>
<td>Regenxbio</td>
<td>Buy</td>
<td>-4.50%</td>
<td>$14.90M</td>
<td>-18.25%</td>
</tr>
<tr>
<td>Precigen</td>
<td>Buy</td>
<td>-3.09%</td>
<td>$21K</td>
<td>-42.02%</td>
</tr>
<tr>
<td>MeiraGTx Hldgs</td>
<td>Buy</td>
<td>948.53%</td>
<td>$9.58M</td>
<td>-48.18%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Sage Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages indicating a decline. However, it ranks at the top for Return on Equity, showing a positive trend. Overall, Sage Therapeutics is positioned in the middle compared to its peers based on the provided metrics.
<h3>Delving into Sage Therapeutics's Background</h3>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Sage Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Sage Therapeutics faced challenges, resulting in a decline of approximately -83.56% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sage Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -747.33%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -18.84%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Sage Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -16.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Sage Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/SAGE/earnings">To track all earnings releases for Sage Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAGE

What to Expect from Sage Therapeutics's Earnings

ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.
Analysts are estimating that ArcBest will report an earnings per share (EPS) of $0.52.
The market awaits ArcBest's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.28, which was followed by a 0.0% drop in the share price the next day.
Here's a look at ArcBest's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.05</td>
<td>1.83</td>
<td>2.08</td>
<td>1.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.33</td>
<td>1.64</td>
<td>1.98</td>
<td>1.34</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866960_0.png" alt="eps graph" />
<h3>Performance of ArcBest Shares</h3>
Shares of ArcBest were trading at $58.42 as of April 25. Over the last 52-week period, shares are down 47.33%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Opinions on ArcBest</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding ArcBest.
With 13 analyst ratings, ArcBest has a consensus rating of Neutral. The average one-year price target is $95.54, indicating a potential 63.54% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Marten Transport, Werner Enterprises and Heartland Express, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Marten Transport, with an average 1-year price target of $19.0, suggesting a potential 67.48% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Werner Enterprises, with an average 1-year price target of $31.0, suggesting a potential 46.94% downside.</li>
<li>Analysts currently favor an Underperform trajectory for Heartland Express, with an average 1-year price target of $9.0, suggesting a potential 84.59% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Marten Transport, Werner Enterprises and Heartland Express, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ArcBest</td>
<td>Neutral</td>
<td>-8.07%</td>
<td>$82.75M</td>
<td>2.22%</td>
</tr>
<tr>
<td>Marten Transport</td>
<td>Outperform</td>
<td>-3.16%</td>
<td>$33.34M</td>
<td>0.56%</td>
</tr>
<tr>
<td>Werner Enterprises</td>
<td>Neutral</td>
<td>-8.18%</td>
<td>$90.90M</td>
<td>0.82%</td>
</tr>
<tr>
<td>Heartland Express</td>
<td>Underperform</td>
<td>-11.90%</td>
<td>$27.38M</td>
<td>-0.22%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ArcBest ranks in the middle for revenue growth among its peers. It ranks at the top for gross profit. It ranks in the middle for return on equity.
<h3>All You Need to Know About ArcBest</h3>
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
<h3>Understanding the Numbers: ArcBest's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, ArcBest faced challenges, resulting in a decline of approximately -8.07% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: ArcBest's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.9% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): ArcBest's ROE excels beyond industry benchmarks, reaching 2.22%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ArcBest's ROA excels beyond industry benchmarks, reaching 1.2%. This signifies efficient management of assets and strong financial health.
Debt Management: ArcBest's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/ARCB/earnings">To track all earnings releases for ArcBest visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCB

Uncovering Potential: ArcBest's Earnings Preview

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect NeoGenomics to report an earnings per share (EPS) of $-0.01.
The market awaits NeoGenomics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.01 in the last quarter, leading to a 2.54% increase in the share price on the following day.
Here's a look at NeoGenomics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.01</td>
<td>0</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.05</td>
<td>0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>4.0%</td>
<td>18.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866952_0.png" alt="eps graph" />
<h3>Market Performance of NeoGenomics's Stock</h3>
Shares of NeoGenomics were trading at $10.27 as of April 25. Over the last 52-week period, shares are down 29.74%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about NeoGenomics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding NeoGenomics.
The consensus rating for NeoGenomics is Buy, derived from 5 analyst ratings. An average one-year price target of $17.0 implies a potential 65.53% upside.
<h3>Comparing Ratings with Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Astrana Health, OPKO Health and Pediatrix Medical Group, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Astrana Health, with an average 1-year price target of $47.4, suggesting a potential 361.54% upside.</li>
<li>Analysts currently favor an Buy trajectory for OPKO Health, with an average 1-year price target of $2.75, suggesting a potential 73.22% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Pediatrix Medical Group, with an average 1-year price target of $17.5, suggesting a potential 70.4% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary outlines pivotal metrics for Astrana Health, OPKO Health and Pediatrix Medical Group, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeoGenomics</td>
<td>Buy</td>
<td>10.57%</td>
<td>$77.26M</td>
<td>-1.69%</td>
</tr>
<tr>
<td>Astrana Health</td>
<td>Buy</td>
<td>88.43%</td>
<td>$50.48M</td>
<td>-0.98%</td>
</tr>
<tr>
<td>OPKO Health</td>
<td>Buy</td>
<td>0.95%</td>
<td>$84.66M</td>
<td>1.01%</td>
</tr>
<tr>
<td>Pediatrix Medical Group</td>
<td>Neutral</td>
<td>1.19%</td>
<td>$128.53M</td>
<td>4.07%</td>
</tr>
</tbody>
</table>

Key Takeaway:
NeoGenomics ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. For Return on Equity, NeoGenomics is at the bottom.
<h3>About NeoGenomics</h3>
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
<h3>A Deep Dive into NeoGenomics's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining NeoGenomics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.57% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeoGenomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -8.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NeoGenomics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.93%, the company may face hurdles in achieving optimal financial returns.
Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/NEO/earnings">To track all earnings releases for NeoGenomics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: NeoGenomics's Quarterly Earnings

Press Releases

Nukkleus Management Reflects on the Growing Appetite for Defense Innovations

Real Estate

Nukkleus Inc. Successfully Resolves Nasdaq Delisting Threat, Achieving Compliance Across All Key Parameters

Small Cap

How Growing Number of Industries are Leveraging Artificial Intelligence to Create Lucrative Revenue Opportunities

Landmark $8.7 Billion Defense Deal Highlights Israel's Innovation, as Nukkleus Aligns with Growing Air Defense Momentum

Nukkleus Appoints Brigadier General (Ret.) Mark Beesley as Strategic Advisor for Defense Acquisitions

Nukkleus Sees Accelerating Opportunities in Air Defense Thanks to Trump Executive Order to Develop U.S. 'Iron Dome'

Nukkleus Expands Its Focus on the Defense Sector, Strengthens Capital Structure as it takes Initial Steps Toward Star 26 Acquisition

Nukkleus Advisory Board Member Brigadier General (Ret.) Mark Beesley Highlights Rimon's Strategic Role in Trump's 'Golden Dome' Missile Defense Initiative

Market News Alert: After Nukkleus' 1000% Rise, Wall Street Thinks Silynxcom Could be a Potential Multibagger Israeli Defense Tech Stock

Market Alert: Silynxcom's Drone Awareness Technology Positioned for Growth as Governments Allocate Billions to Counter-Drone Programs Following Russia-Ukraine "Drone War" Lessons

AVAI

SYNX

ZENA

누클레우스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>)의 주가가 금요일 약 44% 급등했다. 이는 회사가 <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43042115/nukkleus-shares-are-soaring-after-hours">나스닥 상장 요건</a>을 재확인했다고 발표한 후 계속된 모멘텀으로 보인다.
알아두어야 할 사항: 이 전략적 인수 회사는 필수 기준을 충족했다는 통지를 받아 이전의 컴플라이언스 문제를 해결했다.
이를 달성하기 위해 누클레우스는 10월에 1대 8의 주식 병합을 시행하여 발행 주식을 1,690만 주에서 약 210만 주로 줄였다. 이러한 조치로 나스닥은 1월 21일로 예정되어 있던 청문회를 취소하고 회사의 계속 상장을 확인했다.
이 해결은 누클레우스에게 전환점을 의미하며, 잠재적인 상장 폐지에 대한 우려를 덜어주고 규제 기준을 충족할 수 있다는 투자자 신뢰를 높였다.
NUKK 주가 동향: 누클레우스 주식은 금요일 43.69% 급등한 29.50달러에 마감했다. 이후 시간외 거래에서 8.85% 추가 상승했다.
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-739618" style="width: 523px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17124446/Screenshot-2025-01-17-at-12.43.59-1024x525.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17124446/Screenshot-2025-01-17-at-12.43.59-1024x525.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17124446/Screenshot-2025-01-17-at-12.43.59-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17124446/Screenshot-2025-01-17-at-12.43.59-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17124446/Screenshot-2025-01-17-at-12.43.59.png 1513w" alt="" width="1024" height="525" /></a></figure>
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">대법원, 트럼프 취임식 앞두고 틱톡 금지 유지: &#8216;잘 뒷받침된 국가 안보 우려&#8217;를 위한 필요</a></li>
</ul>
이미지는 Shutterstock 제공.


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

버서스 시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>)의 주가는 회사가 <a href="https://www.benzinga.com/quote/VS/news" target="_blank" rel="noopener" data-google-interstitial="false">국제적인 입지</a>를 성장시키기 위한 전략의 일환으로 회사가 브라질 시장으로의 확장을 발표한 후 급등했다.
버서스 시스템즈의 주가가 금요일 프리마켓 거래에서 71.2% 상승하여 $3.39에 거래되었다.
금요일 프리마켓 거래에서 움직임이 있는 다른 주식들도 있다.
<h3 class="wp-block-heading">상승 종목</h3>
<ul>
<li>아이스페시맨(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>)은 hMPV 바이오스펙리멘의 공급자를 확보했다고 발표한 후 프리마켓 거래에서 49.1% 상승하여 $4.25에 거래되었다.</li>
<li>누클레우스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>)는 나스닥 상장 폐지 통지를 해결하고 상장 기준을 준수하고 있다고 발표한 후 33% 상승하여 $27.30에 거래되었다.</li>
<li>사이닝 데이 스포츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>)는 목요일에 9% 하락한 후 금요일 프리마켓 거래에서 19.2% 상승하여 $2.55에 거래되었다.</li>
<li>유클라우드링크 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>)는 WH 스미스 PLC의 인모션 엔터테인먼트 그룹(InMotion Entertainment Group)과 최근 협력 계약을 체결했다고 발표한 후 프리마켓 거래에서 18.7% 상승하여 $1.59에 거래되었다.</li>
<li>트레저 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>)는 목요일에 약 7% 상승한 후 프리마켓 거래에서 15.3% 상승하여 $0.2471에 거래되었다.</li>
<li>TXNM 에너지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>)는 프리 마켓 거래에서 14.3% 상승하여 $55.99에 거래되었다.</li>
<li>트리스 메디컬 컨셉츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>)는 2024년 4분기 및 전체 연도 매출에 대한 예비, 감사되지 않은 수치를 발표한 후 프리마켓 거래에서 14% 상승하여 $9.40에 거래되었다.</li>
<li>LSI 인더스트리즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>)는 2025 회계연도 2분기 실적을 2025년 1월 23일 목요일 시장 개장 전 발표할 것이라고 발표한 후 프리마켓 거래에서 8.8% 상승하여 $21.00에 거래되었다.</li>
<li>오소픽스 메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>)은 프리마켓 거래에서 8.1% 상승하여 $19.39에 거래되었다.</li>
</ul>
<h3 class="wp-block-heading">하락 종목</h3>
<ul>
<li>비즐리 브로드캐스트 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>)은 프리마켓 거래에서 43.8% 하락하여 $5.00에 거래되었다.</li>
<li>비아비 솔루션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>)은 프리마켓 거래에서 19.3% 하락하여 $8.10에 거래되었다. 비아비 솔루션은 2025 회계연도 2분기 재무 실적을 2025년 1월 30일 목요일 시장 종료 후 발표할 것이다.</li>
<li>FOXO 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>)는 목요일에 58% 상승한 후 금요일 프리마켓 거래에서 18.4% 하락하여 $0.2566에 거래되었다.</li>
<li>네이처스 선샤인 프로덕츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>)는 프리마켓 거래에서 15.9% 하락하여 $12.00에 거래되었다.</li>
<li>엘리시오 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>)는 프리마켓 거래에서 12.8% 하락하여 $5.61에 거래되었다.</li>
<li>G. 윌리푸드 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WILC#NASDAQ">WILC</a>)는 프리마켓 거래에서 11.5% 하락하여 $14.01에 거래되었다.</li>
<li>바이카라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>)는 목요일에 8% 하락한 후 금요일 프리마켓 거래에서 11.5% 하락하여 $10.51에 거래되었다.</li>
<li>J.B. 헌트 트랜스포트 서비스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>)는 회사가 목요일에 예상보다 낮은 4분기 실적을 발표한 후 프리마켓 거래에서 10.3% 하락하여 $167.00에 거래되었다.</li>
<li>MiMedx 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>)은 프리마켓 거래에서 6.3% 하락하여 $8.50에 거래되었다.</li>
<li>알보텍(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>)은 회사가 $500만 공모 가격을 발표한 후 프리마켓 거래에서 5% 하락하여 $12.60에 거래되었다.</li>
<li></li>
</ul>
이것도 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EA%B8%88%EC%9A%94%EC%9D%BC-%EC%A3%BC%EB%AA%A9%ED%95%B4%EC%95%BC-%ED%95%A0-%EC%A3%BC%EC%8B%9D-%ED%8C%A8%EC%8A%A4%EB%84%90-jb-%ED%97%8C%ED%8A%B8-%EC%8A%A4%ED%85%8C%EC%9D%B4%ED%8A%B8-%EC%8A%A4/" target="_blank" rel="noopener">금요일 주목해야 할 주식: 패스널, JB 헌트, 스테이트 스트리트, 코보 및 슐럼버거</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1" target="_blank" rel="noopener" data-google-interstitial="false">개별 종목</a>에 대한 최신 뉴스를 확인할 수 있는 소스이다.
2024년 12월 벤징가 프로에서 가장 많이 검색된 주식들에 대한 정보이다. 현재 주가와 연초 대비 성과는 12월 31일 기준이며 배당금은 포함되어 있지 않았다. 11월의 데이터는 추적되지 않았다.
1. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>현재가: $403.84</li>
<li>52주 범위: $138.80 ~ $488.54</li>
<li>연초 대비 수익률: +62.6%</li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%8F%85%EC%A0%90-9%EC%9B%94-%EB%B2%A4%EC%A7%95%EA%B0%80-%ED%94%84%EB%A1%9C%EC%97%90%EC%84%9C-%EA%B0%80%EC%9E%A5-%EB%A7%8E%EC%9D%B4-%EA%B2%80%EC%83%89%EB%90%9C-%EC%83%81%EC%9C%84-20%EA%B0%9C/" target="_blank" rel="noopener">9월</a>/<a href="https://kr.benzinga.com/news/usa/stocks/%EB%8F%85%EC%A0%90-%EB%B2%A4%EC%A7%95%EA%B0%80-%ED%94%84%EB%A1%9C%EC%97%90%EC%84%9C-10%EC%9B%94-%EA%B0%80%EC%9E%A5-%EB%A7%8E%EC%9D%B4-%EA%B2%80%EC%83%89%EB%90%9C-%EC%83%81%EC%9C%84-20%EA%B0%9C/" target="_blank" rel="noopener">10월</a> 순위: 3위/1위</li>
</ul>
2. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>현재가: $30.48</li>
<li>52주 범위: $17.25 ~ $122.90</li>
<li>연초 대비 수익률: +6.8%</li>
<li>9월/10월 순위: 7위/5위</li>
</ul>
3. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>현재가: $134.29</li>
<li>52주 범위: $47.32 ~ $152.89</li>
<li>연초 대비 수익률: +178.8%</li>
<li>9월/10월 순위: 1위/2위</li>
</ul>
4. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>현재가: $586.08</li>
<li>52주 범위: $466.44 ~ $609.07</li>
<li>연초 대비 수익률: +24.0%</li>
<li>9월/10월 순위: 2위/4위</li>
</ul>
추가 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EB%8B%A4%EC%9A%B0%EC%A1%B4%EC%8A%A4-2024-%EC%A0%90%EC%88%98%ED%8C%90-%EC%83%81%EC%9C%84-5%EA%B0%9C-%EC%8A%B9%EC%9E%90%EC%99%80-%ED%8C%A8%EC%9E%90-%EC%95%84%EB%A7%88%EC%A1%B4-%EC%97%94%EB%B9%84/" target="_blank" rel="noopener">다우 존스 2024 점수판: 상위 5개 승자, 패자 — 그리고 아마존, 엔비디아가 2025년을 어떻게 재편할 수 있을지</a>
5. 사운드하운드 AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>)
<ul>
<li>현재가: $19.84</li>
<li>52주 범위: $1.62 ~ $24.98</li>
<li>연초 대비 수익률: +853.9%</li>
<li>9월/10월 순위: 상위 20위 안에 없음/상위 20위 안에 없음</li>
</ul>
6. 팔란티어 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)
<ul>
<li>현재가: $75.63</li>
<li>52주 범위: $15.67 ~ $77.98</li>
<li>연초 대비 수익률: +356.2%</li>
<li>9월/10월 순위: 12위/14위</li>
</ul>
7. 퀀텀 컴퓨팅 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>)
<ul>
<li>현재가: $16.55</li>
<li>52주 범위: $0.35 ~ $27.15</li>
<li>연초 대비 수익률: +1,759.6%</li>
<li>9월/10월 순위: 상위 20위 안에 없음/상위 20위 안에 없음</li>
</ul>
8. 리제티 컴퓨팅 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)
<ul>
<li>현재가: $15.26</li>
<li>52주 범위: $0.66 ~ $19.35</li>
<li>연초 대비 수익률: +1,558.7%</li>
<li>9월/10월 순위: 상위 20위 안에 없음/상위 20위 안에 없음</li>
</ul>
9. 마이크로스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)
<ul>
<li>현재가: $289.62</li>
<li>52주 범위: $43.89 ~ $542.99</li>
<li>연초 대비 수익률: +322.7%</li>
<li>9월/10월 순위: 상위 20위 안에 없음/16위</li>
</ul>
10. 누클레우스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>)
<ul>
<li>현재가: $36.67</li>
<li>52주 범위: $1.30 ~ $78.32</li>
<li>연초 대비 수익률: +58.6%</li>
<li>9월/10월 순위: 상위 20위 안에 없음/상위 20위 안에 없음</li>
</ul>
추가 언급: 다음 주식들은 2024년 12월 벤징가 프로에서 11위부터 20위까지 가장 많이 검색된 종목들이다.
<ol start="11">
<li>브로드컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</li>
<li>클린스파크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>)</li>
<li>어드밴스드 마이크로 디바이시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</li>
<li>일라이 릴리 앤 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>실스크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>)</li>
<li>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)</li>
<li>D-웨이브 퀀텀 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)</li>
<li>델 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</li>
<li>월마트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)</li>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)</li>
</ol>
중요한 이유: 테슬라는 또 한 달 동안 벤징가 프로에서 가장 많이 검색된 종목으로 12월의 왕좌를 차지했다. 이 주식은 매달 사이트에서 가장 많이 검색되는 종목 중 하나이다.
슈퍼 마이크로 컴퓨터는 12월에 2위로 상승했다. 주식이 크게 하락한 월과 함께 관심이 급증했다.
엔비디아는 12월에 3위를 차지했으며, 이는 몇 달 간의 추적에서 가장 낮은 순위이다.
여러 회사들이 가장 많이 검색된 종목 목록에 처음 등장했다. <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42380768/quantum-computing-stocks-roundup-d-wave-rigetti-ionq-lead-the-charge-with-explosive-growth">양자 컴퓨팅</a> 주식 테마가 12월 월간 순위에 나타났다. 퀀텀 컴퓨팅, 리제티, D-웨이브 퀀텀은 모두 12월에 가장 많이 검색된 종목 상위 20위 안에 포함되었다.
다른 신입 주식으로는 인기 인공지능(AI) 플레이이자 숏 스퀴즈 후보인 사운드하운드 AI가 포함되었다. 이 주식은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-d-%EC%9B%A8%EC%9D%B4%EB%B8%8C-%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EC%82%AC/" target="_blank" rel="noopener">벤징가 스톡 위스퍼 지수</a>에서 여러 번 강조되었으며, 회사 경영진은 최근 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%8F%85%EC%A0%90-%EC%82%AC%EC%9A%B4%EB%93%9C%ED%95%98%EC%9A%B4%EB%93%9C-ai%EC%9D%98-ceo%EA%B0%80-945-%EC%84%B1%EC%9E%A5%EC%97%90-%EB%8C%80%ED%95%B4-%EC%96%B8%EA%B8%89%ED%95%98%EB%A9%B0-%EC%9A%B0/" target="_blank" rel="noopener">벤징가와 인터뷰</a>를 했다.
마이크로스트레티지는 가장 큰 비트코인 보유자 중 하나로 9위에 올랐다. 9월 16위에서 상승했다. 이 주식은 여전히 비트코인의 대리 역할을 하고 있지만, 비트코인 ETF의 출현으로 2025년 투자자의 관심을 지켜보는 흥미로운 사례가 될 것이다.
누클레우스도 10위에 처음 등장했으며, 이번 달 포함이 일회성인지 아니면 투자자 모멘텀의 시작인지 지켜볼 가치가 있다.
ETF 부문에서는 SPDR S&amp;P 500 ETF Trust가 4위를 차지했으며 여전히 가장 많이 주시되는 ETF 중 하나이다. 나스닥 100을 추적하는 Invesco QQQ Trust ETF는 20위로 하락했으며, 10월에 15위, 9월에 6위를 기록했다.
트럼프 미디어 앤 테크놀로지 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)는 10월에 3위를 차지했으나 20위 안에서 제외되었다. 이는 주식이 2024년 선거를 앞두고 모멘텀을 얻었고 이 움직임이 단기적이었음을 나타낼 수 있다. 도널드 트럼프 당선자의 취임식이 1월에 예정되어 있어 주식이 가격과 벤징가 독자들 사이의 관심이 상승하는지를 지켜보는 것이 중요한다.
애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)은 12월에 큰 놀라움 중 하나였다. 이 주식은 정기적으로 상위 10개 가장 많이 검색된 종목 중 하나로 10월에는 8위를 차지했지만, 12월에는 25위로 하락했다.
전반적으로 12월 한 달 동안 10월의 상위 10개 종목 중 4개가 동일하게 유지되었고, 10월의 상위 20개 종목 중 8개가 동일하게 유지되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/10/41584466/these-10-stocks-were-the-best-s-p-500-performers-in-2017-when-trump-was-president-will-history-r">이 10개 종목은 2017년 트럼프 대통령 재임 시 최고의 S&amp;P 500 성과를 낸 주식들입니다. 역사가 반복될까요?</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

뉴클러스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) 주가는 수요일(18일) 방위산업체 스타 26 캐피털(Star 26 Capital)의 51% 지분을 인수했다는 발표 이후 지속적인 모멘텀으로 상승세를 보이고 있다. <a href="//www.benzinga.com/quote/NUKK/news"" target="_blank" rel="noopener">알아야 할 내용은 다음과 같다.</a>
알아야 할 내용: 뉴클러스는 화요일(17일) 이스라엘의 아이언 돔 미사일 방어 시스템의 핵심 부품 공급업체이자 국방 및 정보 기관을 위한 전술 차량 개발업체인 리몬(RIMON)의 지분 95%를 보유한 스타 26의 지배 지분을 인수했다고 밝혔다.
이번 인수는 핀테크에 뿌리를 둔 뉴클러스가 방위 분야로 전략적으로 전환하는 것을 의미한다. 주말에 마무리된 이번 거래의 총 인수 가격은 현금, 약속어음, 뉴클러스 보통주, 뉴클러스 추가 주식 매입권을 포함해 2,600만 달러에 달한다. 또한 스타 26의 나머지 지분을 인수할 수 있는 옵션도 확보했다.
리몬은 발전기, 마스트 및 조명 솔루션에 대한 독점 유통 계약과 정찰 차량, 이동 지휘 유닛 및 위성 플랫폼의 설계 및 엔지니어링을 담당하고 있다. 새로 임명된 누클레우스 CEO인 매니 샬롬(Manny Shalom)은 중동의 지정학적 긴장과 우크라이나 전쟁으로 인해 이스라엘 기업의 방위 관련 투자가 증가하고 있다며 방위 산업의 성장 잠재력을 강조했다.
샬롬은 "중요한 방위 시스템에 대한 리몬의 전문성과 라파엘(Rafael) 및 엘비트 시스템즈(Elbit Systems)와 같은 주요 방위 수출업체와의 파트너십을 통해 혁신적인 방위 솔루션을 제공하는 뉴클러스의 역량이 강화될 것"이라고 말했다.
뉴클러스의는 리몬의 방위 전문성과 파트너십을 활용하여 미국과 이스라엘 시장 기회를 활용하는 동시에 성장을 촉진하기 위한 인수 및 자금 조달 이니셔티브를 추진한다는 목표다.
회사의 전체 확장 전략에 따라 뉴클러스는 스타 26을 사업 구조에 통합하고 운영을 확장하며 은행, 부동산 및 코워킹 스페이스 기업을 위한 머천트 뱅크 역할을 할 계획이다.
뉴클러스 주가 움직임: 수요일 세션에서 변동성 때문에 여러 차례 거래가 중단되었다. <a href="//pro.benzinga.com/dashboard"" target="_blank" rel="noopener">벤징가 프로에</a> 따르면 수요일 주가는 327.53% 급등한 50.79달러로 마감되었다.
이미지 출처: Pixabay
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

뉴클러스 주가 327% 급등, 도대체 무슨 일 일까?

화요일(17일) 미국 증시는 11월 소매판매 발표 이후 주요 지수가 하락했다. 소매판매 데이터는 연준의 내년 금리인하 지연 가능성에 대한 우려를 불러일으켰다.
S&amp;P 500 지수와 다우존스 산업평균지수는 각각 0.4%, 0.6% 하락했고, 나스닥 100 지수는 지정학적 긴장감으로 반도체주가 하락세를 주도하며 0.3% 하락했다.
화요일에 개인 투자자와 트레이더들의 주목을 받은 주식은 다음과 같다.
1. 뉴클러스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>)
뉴클러스 주가는 754.68% 급등하여 11.88로 마감했다. 주가는 장중 최고가 17.66달러, 최저가 1.84달러를 기록했으며 52주 범위는 34.16~0.40달러다.
이러한 급격한 상승은 뉴클러스가 이스라엘의 아이언 돔 미사일 방어 시스템 공급업체인 리몬(RIMON)의 지분을 상당 부분 보유하고 있는 스타 26 캐피탈(Star 26 Capital Inc.)의 지분 51%를 인수한다는 발표에 따른 것이었다. 이번 인수를 통해 뉴클러스는 방위 산업에 대한 야망을 <a href="https://www.benzinga.com/24/12/42535878/why-nukkleus-stock-is-gaining-tuesday">더욱 강화할 것이다.</a>
2. 마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
마이크론 테크놀로지는 0.31% 소폭 상승하여 108.60 달러로 마감했다. 주가는 최고가 110.49 달러에서 최저 107.68 달러 사이에서 변동했으며 52주 범위는 157.54~78.63달러다. 마이크론은 1분기 실적을 발표할 예정이며, 애널리스트들은 매출이 전년 대비 크게 증가한 87억 2천만 달러에 달할 것으로 <a href="https://www.benzinga.com/24/12/42541544/micron-q1-earnings-preview-analyst-estimates-why-company-is-well-positioned-heading-into-2025">예상하고 있다.</a> 마이크론은 최근 몇 분기 동안 지속적으로 예상치를 상회하는 실적을 달성했다.
3. 테바 파마슈티컬 인더스트리즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)
테바 파마슈티컬은 주가가 26.47% 상승하여 20.88달러로 마감했다. 주가는 장중 최고가 21.05달러, 최저가 19.03달러를 기록했으며 52주 범위는 21.05~10달러다. 이러한 상승은 염증성 장 질환을 표적으로 하는 단일 클론 항체에 대한 2b상 연구가 성공적으로 완료되어 임상적 관해율에서 <a href="https://www.benzinga.com/24/12/42531132/why-are-teva-and-sanofi-stocks-trading-higher-on-tuesday" target="_blank" rel="noopener">긍정적인</a> 결과를 달성한 데 따른 것이었다.
4. 퀀텀 컴퓨팅 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>)
퀀텀 컴퓨팅 주가는 51.53% 상승하여 16.79달러로 마감했다. 주식의 장중 범위는 18.06~12.60달러였고, 52주 범위는 18.06~0.35달러였다. 이번 주가 급등은 퀀텀 컴퓨팅이 데이터 품질과 정확성을 향상시키기 위해 Dirac-3 머신을 활용하여 이미징 및 데이터 처리를 지원하는 NASA와의 <a href="https://www.benzinga.com/24/12/42533581/quantum-computing-stock-is-rising-tuesday-heres-why" target="_blank" rel="noopener">주요 계약</a>을 발표한 후 나타났다.
5. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라는 3.64% 상승하여 479.86달러에 마감했다. 장중 최고가 483.99달러, 최저가 457.51달러였으며 52주 범위는 483.99~138.8달러였다. 애널리스트인 댄 아이브스는 테슬라가 도널드 트럼프 대통령 당선인의 행정부에서 인공지능과 규제 완화에 힘입어 예상되는 기술 부문 확장의 <a href="https://www.benzinga.com/markets/equities/24/12/42522531/tesla-will-be-the-biggest-winner-in-the-trump-era-says-dan-ives-predicts-nasdaq-at-25000-in-18-months-get-the-popcorn-out" target="_blank" rel="noopener">주요 수혜자</a>가 될 것이라고 예측했다.
이미지: Shutterstock.com
벤징가의 <a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News" target="_blank" rel="noopener">프리마켓 동향 및 뉴스</a>로 하루의 거래를 준비하세요.
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

TEVA

화요일 주목받은 주식: 뉴클러스, 마이크론, 테바 파마슈티컬, 퀀텀 컴퓨팅 및 테슬라

Comments

Nukkleus

뉴스

에 대한 최신 뉴스 Nukkleus (NASDAQ:NUKK) 주식

토요일, 1월 18, 2025

금요일, 1월 17, 2025

수요일, 1월 01, 2025

수요일, 12월 18, 2024

뉴스

파트너 / 기고자

벤징가 글로벌